4//SEC Filing
ASADORIAN RAFFI 4
Accession 0001209191-22-009346
CIK 0001427925other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 4:50 PM ET
Size
9.5 KB
Accession
0001209191-22-009346
Insider Transaction Report
Form 4
ASADORIAN RAFFI
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-11+235,000→ 235,000 totalExercise: $0.40Exp: 2032-02-11→ Common Stock (235,000 underlying) - Award
Common Stock
2022-02-11+117,500→ 376,015 total - Tax Payment
Common Stock
2022-02-11$0.40/sh−7,927$3,182→ 368,080 total
Footnotes (4)
- [F1]The restricted stock units shall vest in three equal consecutive annual installments on February 11, 2023, February 11, 2024 and February 11, 2025.
- [F2]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F3]Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
- [F4]On February 11, 2022, the reporting person was granted an option to purchase 235,000 shares of common stock. One fourth (1/4th) of the option shares shall vest on the one year anniversary of the grant date, and the remaining balance of the option shares shall vest in 36 equal consecutive monthly installments thereafter until fully vested so long as the reporting person remains in continuous service through such applicable vesting periods.
Documents
Issuer
ACELRX PHARMACEUTICALS INC
CIK 0001427925
Entity typeother
Related Parties
1- filerCIK 0001628970
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 4:50 PM ET
- Size
- 9.5 KB